Verge Genomics Secures $98 Million in New Financing
Summary
“We are thrilled that multiple stakeholders in our space, from leading pharmaceutical companies to healthcare and technology investors, recognize the potential of our human-centric AI platform to transform drug discovery for the most challenging diseases of our generation,” said Alice Zhang, co-founder and CEO of Verge Genomics. Additionally, Verge will continue to expand its proprietary technology to enable improvements in many steps of the drug discovery process including translational medicine and clinical development. “Verge has uniquely positioned itself to harness this opportunity, having developed both a world-class AI discovery platform and the most comprehensive neurodegenerative genomic database of human patients in the world. Verge applies machine learning to reveal new targets from human datasets and develops drugs with greater probabilities of success using its human-centric biology and chemistry platforms. Verge has further demonstrated the power of its platform by delivering a broad preclinical and discovery pipeline spanning diverse therapeutic areas, with its first program entering the clinic in 2022.